Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Diabetes and Heart Failure
Phase of Trial: Phase IV
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Empagliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms EMBRACE-HF
- 14 Jul 2017 Status changed from not yet recruiting to recruiting.
- 07 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jun 2017.
- 24 Apr 2017 Planned initiation date changed from 1 Mar 2017 to 1 May 2017.